A Randomised Phase II Trial of Adjuvant Avelumab in Patients with Early Stage Merkel Cell Carcinoma

  • Xu, Wen (Primary Chief Investigator (PCI))
  • Poulsen, Michael (Chief Investigator (CI))
  • Atkinson, Victoria (Chief Investigator (CI))
  • Fogarty, Gerald B (Chief Investigator (CI))
  • Veness, Michael (Chief Investigator (CI))
  • Smithers, Bernard Mark (Chief Investigator (CI))
  • Gyorki, David E (Chief Investigator (CI))
  • Mar, Victoria (Chief Investigator (CI))
  • Howle, Julie (Chief Investigator (CI))
  • Guminski, Alexander (Chief Investigator (CI))

Project: Research

Project Details

Short titleAdjuvant therapy for Merkel Cell Cancer
Effective start/end date1/04/1931/03/24
  • γδ T cells in merkel cell carcinomas have a proinflammatory profile prognostic of patient survival

    Gherardin, N. A., Waldeck, K., Caneborg, A., Martelotto, L. G., Balachander, S., Zethoven, M., Petrone, P. M., Pattison, A., Wilmott, J. S., Quiñones-Parra, S. M., Rossello, F., Posner, A., Wong, A., Weppler, A. M., Shannon, K. F., Hong, A., Ferguson, P. M., Jakrot, V., Raleigh, J., Hatzimihalis, A., & 12 othersNeeson, P. J., Deleso, P., Johnston, M., Chua, M., Becker, J. C., Sandhu, S., McArthur, G. A., Gill, A. J., Scolyer, R. A., Hicks, R. J., Godfrey, D. I. & Tothill, R. W., 1 Jun 2021, In: Cancer Immunology Research. 9, 6, p. 612-623 12 p.

    Research output: Contribution to journalArticleResearchpeer-review

    8 Citations (Scopus)